Evaluation of Matrix Metalloproteinase-9 (MMP-9) and its tissue inhibitor of metalloproteinase-1 (Timp-1) in patients with coronary syndromes after percutaneous intervention(PCI)

被引：0

作者：

Revnic, F. ^{[1
]}

Revnic, C. R. ^{[2
]}

Nica, A. ^{[3
]}

Ginghina, C. ^{[3
]}

Prada, G. ^{[3
]}

Gradinaru, D. ^{[3
]}

Prada, S. ^{[1
]}

Sonea, C. ^{[4
]}

Pena, C. ^{[1
]}

机构：

[1] NIGG Ana Aslan, Bucharest 99101, Romania

[2] Univ Paris 6 Pierre & Marie Curie, Paris, France

[3] Univ Med & Pharm Carol Davila, Dionisie Lupu Str 37,Sect 1, Bucharest 71237, Romania

[4] USAMV, Bucharest, Romania

来源：

CORONARY ARTERY DISEASE: 2011 UPDATE: FROM PREVENTION TO INTERVENTION | 2011年

关键词：

coronary atherosclerosis; matrix metalloproteinase-9 (MMP-9); tissue inhibitor of metalloproteinase-1 (TIMP-1); high sensitivity CRP; myocardial infarction; C-REACTIVE PROTEIN; INFLAMMATION; ELEVATION;

D O I：

暂无

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Atherosclerosis and inflammation are two key factors in developing coronary artery disease (CAD). The presence of inflammation is reflected by the hs-CRP and MMP-9 produced by macrophages from the atherosclerotic plaques and directs the progression of coronary artery disease to acute coronary syndromes. We aimed to see the relationship between MMP-9, TIMP-1 and hs-CRP in patients with coronary atherosclerosis. MMP-9, TIMP-1 and hs-CRP reflects the presence of inflammation and the evolution of stable atherosclerotic plaques into unstable ones and developing of acute coronary syndromes.

引用

页码：49 / 52

页数：4

共 6 条

[1] C-reactive protein elevation and disease activity in patients with coronary artery disease [J].